Onkolojik Tedaviye Bağlı Aritmilerde Tanı ve Tedavi Yaklaşımları

Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, CammJ, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekval TM, Spaulding C, Van Veld- huisen DJ. 2015 ESC Guidelinesforthemanagement of patientswithventri- culararrhythmiasandtheprevention of suddencardiacdeath: theTask Force forthe Management of PatientswithVentricularArrhythmiasandthePreven- tion of SuddenCardiacDeath of theEuropeanSociety of Cardiology (ESC). Endorsedby: AssociationforEuropeanPaediatricandCongenitalCardiology (AEPC). EurHeart J 2015;36:2793–2867.

Al-Khatib SM, et al. 2017 AHA/ACC/HRS guidelineformanagement of patientswithventriculararrhythmiasandtheprevention of suddencardiacdeath: executivesummary: a report of theAmericanCollege of Cardiology/AmericanHeartAssociationTask Force on ClinicalPracticeGuidelinesandtheHeartRhythmSociety. Circulation. 2017; https://doi.org/10.1161/cir.0000000000000548.

January CT, et al. 2014 AHA/ACC/HRS guidelineforthemanagement of patientswithatrialfibrillation: executivesummary: a report of theAmericanCollege of Cardiology/AmericanHeartAssociationTask Force on practiceguidelinesandtheHeartRhythmSociety. 2014;64:e1–e76 https://doi.org/10.1016/j.jacc.2014.03.022.

Lenihan DJ, Kowey PR. Overviewandmanagement of cardiacadverseeventsassociatedwithtyrosinekinaseinhibitors. Oncologist2013;18:900–908.

Strevel EL, Ing DJ, Siu LL. Molecularlytargetedoncologytherapeuticsandpro- longation of the QT interval. J ClinOncol2007;25:3362–3371.

Drew BJ, et al. Prevention of torsade de pointes in hospitalsettings: a scientificstatementfromtheAmericanHeartAssociationandtheAmericanCollege of Cardiology Foundation. Circulation. 2010;121:1047–60. https://doi.org/10.1161/circulationaha.109.192704.

Frendl G, et al. 2014 AATS guidelinesforthepreventionandmanagement of perioperativeatrialfibrillationandflutterforthoracicsurgicalprocedures. J ThoracCardiovascSurg. 2014;148:e153–93. https://doi.org/10.1016/j.jtcvs.2014.06.036.

Fernando HC, Jaklitsch MT, Walsh GL, Tisdale JE, Bridges CD, Mitchell JD, Shrager JB. TheSociety of ThoracicSurgeonspracticeguideline on theprophylaxisandmanagement of atrialfibrillationassociatedwith general thoracicsurgery: executivesummary. AnnThoracSurg. 2011;92:1144–52. https://doi.org/10.1016/j.athoracsur.2011.06.104.

Johnstone C, Rich SE. Bleeding in cancerpatientsanditstreatment: a review. AnnPalliatMed. 2018; 7(2): 265– 73.

Avvisati G, Tirindelli MC, Annibali O. Thrombocytopeniaandhemorrhagic risk in cancerpatients. CritRevOncolHematol. 2003; 48(Suppl): S13– 6.

Shatzel JJ, Olson SR, Tao DL, McCarty OJT, Danilov AV, DeLoughery TG. Ibrutinib‐associatedbleeding: pathogenesis, managementand risk reductionstrategies. J ThrombHaemost. 2017; 15(5): 835– 47.

Tullemans BME, Heemskerk JWM, Kuijpers MJE. Acquiredplateletantagonism: off‐targetantiplateleteffects of malignancytreatmentwithtyrosinekinaseinhibitors. J ThrombHaemost. 2018; 16(9): 1686– 99.

Steinberg BA, Peterson ED, Kim S, Thomas L, Gersh BJ, Fonarow GC, et al. Useandoutcomesassociatedwithbridgingduringanticoagulationinterruptions in patientswithatrialfibrillation: findingsfromtheOutcomesRegistryforBetterInformedTreatment of AtrialFibrillation (ORBIT‐AF). Circulation. 2015; 131(5): 488– 94.

Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, et al. Perioperativebridginganticoagulation in patientswithatrialfibrillation. N Engl J Med. 2015; 373(9): 823– 33.

Vedovati MC, Giustozzi M, Verdecchia P, Pierpaoli L, Conti S, Verso M, et al. Patientswithcancerandatrialfibrillationtreatedwithdoacs: a prospectivecohortstudy. Int J Cardiol. 2018; 269: 152– 7.

Hart RG, Pearce LA, AguilarMI. Meta‐analysis: antithrombotictherapytopreventstroke in patientswhohavenonvalvularatrialfibrillation. AnnInternMed. 2007; 146(12): 857– 67.

Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR. Incidence of recurrentthromboembolicandbleedingcomplicationsamongpatientswithvenousthromboembolism in relationtobothmalignancyandachievedinternationalnormalizedratio: a retrospectiveanalysis. J ClinOncol. 2000; 18(17): 3078– 83.

Rose AJ, Sharman JP, Ozonoff A, Henault LE, Hylek EM. Effectiveness of warfarinamongpatientswithcancer. J Gen InternMed. 2007; 22(7): 997– 1002.

Noble SI, Finlay IG. Is long‐termlow‐molecular‐weightheparinacceptabletopalliativecarepatients in thetreatment of cancerrelatedvenousthromboembolism? A qualitativestudy. PalliatMed. 2005; 19(3): 197– 201.

Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatranversuswarfarin in patientswithatrialfibrillation. N Engl J Med. 2009; 361(12): 1139– 51.

Patel MR, Mahaffey KW, Garg J, Pan G, SingerDE, Hacke W, et al. Rivaroxabanversuswarfarin in nonvalvularatrialfibrillation. N Engl J Med. 2011; 365(10): 883– 91.

Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of theefficacyandsafety of new oral anticoagulantswithwarfarin in patientswithatrialfibrillation: a meta‐analysis of randomisedtrials. Lancet. 2014; 383(9921): 955– 62.

Chen ST, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, et al. Efficacyandsafety of rivaroxabanversuswarfarin in patientswithNonvalvularatrialfibrillationand a history of cancer: observationsfrom ROCKET AF. EurHeart J QualCareClinOutcomes. 2019; 5(2): 145– 52.

Melloni C, Dunning A, Granger CB, Thomas L, Khouri MG, GarciaDA, et al. Efficacyandsafety of apixabanversuswarfarin in patientswithatrialfibrillationand a history of cancer: insightsfromthe ARISTOTLE trial. Am J Med. 2017; 130(12): 1440– 8.e1.

Fanola CL, Ruff CT, Murphy SA, Jin J, Duggal A, Babilonia NA, et al. Efficacyandsafety of edoxaban in patientswithactivemalignancyandatrialfibrillation: analysis of the ENGAGE AF‐TIMI 48 trial. J AmHeartAssoc. 2018; 7(16): e008987.

Shah S, Norby FL, Datta YH, Lutsey PL, MacLehose RF, Chen LY, et al. Comparativeeffectiveness of direct oral anticoagulantsandwarfarin in patientswithcancerandatrialfibrillation. Blood Adv. 2018; 2(3): 200– 9.

Raskob GE, van Es N, Verhamme P, Carrier M, DiNisio M, Garcia D, et al. Edoxabanforthetreatment of cancer‐associatedvenousthromboembolism. N Engl J Med. 2018; 378(7): 615– 24.

Khorana AA, Noble S, Lee AYY, Soff G, Meyer G, O'Connell C, et al. Role of direct oral anticoagulants in thetreatment of cancer‐associatedvenousthromboembolism: guidancefromthe SSC of the ISTH. J ThrombHaemost. 2018; 16: 1891– 4.

Vrontikis, A.; Carey, J.; Gilreath, J.A.; Halwani, A.; Stephens, D.M.; Sweetenham, J.W. ProposedalgorithmformanagingIbrutinib-relatedatrialfibrillation. Oncology (US) 2016, 30, 970–974

Shah, S.; Norby, F.L.; Datta, Y.H.; Lutsey, P.L.; MacLehose, R.F.; Chen, L.Y.; Alonso, A. Comparativeeffectiveness of direct oral anticoagulantsandwarfarin in patientswithcancerandatrialfibrillation. Blood Adv.2018, 2, 200–209.

Xiang, E.; Ahuja, T.; Raco, V.; Cirrone, F.; Green, D.; Papadopoulos, J. Anticoagulationprescribingpatterns in patientswithcancer. J. Thromb. Thrombolysis 2018, 45, 89–98.

Lee, Y.J.; Park, J.K.; Uhm, J.S.; Kim, J.Y.; Pak, H.N.; Lee, M.H.; Sung, J.H.; Joung, B. Bleeding risk andmajoradverseevents in patientswithcancer on oral anticoagulationtherapy. Int. J. Cardiol. 2016, 203, 372–378.

Friberg, L.; Skeppholm, M.; Terént, A. Benefit of anticoagulationunlikely in patientswithatrialfibrillationand a CHA2DS2-VASc score of 1. J. Am. Coll. Cardiol. 2015, 65, 225–232.

Kalin R, Stanton MS. Currentclinicalissuesfor MRI scanning of pacemakeranddefibrillatorpatients. PacingClinElectrophysiol: PACE. 2005;28:326–8. https://doi.org/10.1111/j.1540-8159.2005.50024.x.

Indik JH, et al. 2017 HRS expertconsensusstatement on magneticresonanceimagingandradiationexposure in patientswithcardiovascularimplantableelectronicdevices. HeartRhythm. 2017;14:e97–e153. https://doi.org/10.1016/j.hrthm.2017.04.025.

Nazarian S, et al. Safety of magneticresonanceimaging in patientswithcardiacdevices. N Engl J Med. 2017;377:2555–64. https://doi.org/10.1056/NEJMoa1604267

Russo RJ, et al. Assessingtherisksassociatedwith MRI in patientswith a pacemakerordefibrillator. N Engl J Med. 2017;376:755–64. https://doi.org/10.1056/NEJMoa1603265.

Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelinesfor Device-BasedTherapy of CardiacRhythmAbnormalities: a report of theAmericanCollege of Cardiology/AmericanHeartAssociationTask Force on PracticeGuidelines (WritingCommitteetoRevisethe ACC/AHA/NASPE 2002 Guideline Update forImplantation of CardiacPacemakersandAntiarrhythmiaDevices): developed in collaborationwiththeAmericanAssociationforThoracicSurgeryandSociety of ThoracicSurgeons. Circulation. 2008;117:e350–408.

Mond HG, Proclemer A. The 11th worldsurvey of cardiacpacingandimplantablecardioverter-defibrillators: calendaryear 2009—a World Society of Arrhythmia’sproject. PacingClin Electrophysiol.2011;34:1013–27.

Crossley GH, Poole JE, Rozner MA, et al. TheHeartRhythmSociety (HRS)/AmericanSociety of Anesthesiologists (ASA) ExpertConsensus Statement on theperioperativemanagement of patientswithimplantabledefibrillators, pacemakersandarrhythmiamonitors: facilitiesandpatientmanagementthisdocumentwasdeveloped as a jointprojectwiththeAmericanSociety of Anesthesiologists (ASA), and in collaborationwiththeAmericanHeartAssociation (AHA), andtheSociety of ThoracicSurgeons (STS). HeartRhythm. 2011;8:1114–54.

Gomez DR, Poenisch F, Pinnix CC, et al. Malfunctions of implantablecardiacdevices in patientsreceiving proton beamtherapy: incidenceandpredictors. Int J RadiatOncolBiolPhys. 2013;87:570–5.

Zweng A, Schuster R, Hawlicek R, Weber HS. Life-threateningpacemakerdysfunctionassociatedwiththerapeuticradiation: a casereport. Angiology. 2009;60:509–12.

.Mouton J, Haug R, Bridier A, et al. Influence of high-energyphotonbeamirradiation on pacemakeroperation. PhysMedBiol. 2002;47:2879–93.

Rodriguez F, Filimonov A, Henning A, et al. Radiation-inducedeffects in multiprogrammablepacemakersandimplantabledefibrillators. PacingClinElectrophysiol. 1991;14:2143–53.

Hurkmans CW, Scheepers E, Springorum BG, Uiterwaal H. Influence of radiotherapy on thelatestgeneration of implantablecardioverter-defibrillators. Int J RadiatOncolBiolPhys. 2005;63:282–9.

Kapa S, Fong L, Blackwell CR, et al. Effects of scatterradiation on ICD and CRT function. PacingClinElectrophysiol. 2008;31:727–32.

Hurkmans CW, Knegjens JL, Oei BS, et al. Management of radiationoncologypatientswith a pacemakeror ICD: a newcomprehensivepracticalguideline in TheNetherlands. DutchSociety of RadiotherapyandOncology (NVRO). RadiatOncol. 2012;7:198.

Elders J, Kunze-Busch M, Jan Smeenk R, Smeets JL. High incidence of implantablecardioverterdefibrillatormalfunctionsduringradiationtherapy: neutrons as a probablecause of softerrors.Europace. 2013;15:60–5.

Uiterwaal GJ, Springorum BG, Scheepers E, et al. Interferencedetection in implantabledefibrillatorsinducedbytherapeuticradiationtherapy. NethHear J. 2006;14:330–4.

Gossman MS, Wilkinson JD, Mallick A. Treatmentapproach, delivery, andfollow-upevaluationforcardiacrhythmdiseasemanagementpatientsreceivingradiationtherapy: retrospectivephysiciansurveysincludingchartreviews at numerouscenters.MedDosim. 2014;39:320–4.

Grant JD, et al. Radiotherapy-inducedmalfunction in contemporarycardiovascularimplantableelectronicdevices: clinicalincidenceandpredictors. JAMA Oncol. 2015;1:624–32. https://doi.org/10.1001/jamaoncol.2015.1787.

Marbach JR, Sontag MR, Van Dyk J, Wolbarst AB. Management of radiationoncologypatientswithimplantedcardiacpacemakers: report of AAPM TaskGroup No. 34.American Association of Physicists in Medicine. MedPhys. 1994;21:85–90.

Solan AN, Solan MJ, Bednarz G, Goodkin MB. Treatment of patientswithcardiacpacemakersandimplantablecardioverter-defibrillatorsduringradiotherapy. Int J RadiatOncolBiolPhys. 2004;59:897–904.

Lester JF, Evans LM, Yousef Z, et al. A nationalaudit of currentcardiacdevicepoliciesfromradiotherapycentresacrossthe UK. ClinOncol (R CollRadiol). 2014;26:45–50.

Scientific B. Therapeuticradiationandimplantabledevicesystems. In. http://www.bostonscientific.com/content/dam/bostonscientific/quality/education-resources/english/ACL_Therapeutic_Radiation_20120925.pdf: 2012.

Medical SJ. Effects of therapeuticradiation on St. JudeMedicalimplantablecardiacrhythmdevices. .In. http://www.sjm.com/~/media/pro/resources/emi/med-dental/fl-therapeutic-r. 2013.

Brambatti M, Mathew R, Strang B, et al. Management of patientswithimplantablecardioverter-defibrillatorsandpacemakerswhorequireradiationtherapy. HeartRhythm. 2015;12:2148–54.

Crossley GH, Poole JE, Rozner MA, et al. TheHeartRhythmSociety (HRS)/AmericanSociety of Anesthesiologists (ASA) ExpertConsensus Statement on theperioperativemanagement of patientswithimplantabledefibrillators, pacemakersandarrhythmiamonitors: facilitiesandpatientmanagementthisdocumentwasdeveloped as a jointprojectwiththeAmericanSociety of Anesthesiologists (ASA), and in collaborationwiththeAmericanHeartAssociation (AHA), andtheSociety of ThoracicSurgeons (STS). HeartRhythm. 2011;8:1114–54.

Makkar A, Prisciandaro J, Agarwal S, et al. Effect of radiationtherapy on permanentpacemakerandimplantablecardioverter-defibrillatorfunction. HeartRhythm. 2012;9:1964–8.